Narcolepsy in Children

Therapy in Sleep Medicine

Volumn , Issue , 2012, Pages 485-492

  Sullivan, Shannon S ^a   Pelayo, Rafael ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882768658     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1703-7.10039-8     Document Type: Chapter

References (75)

1. Peyron C., Faraco J., Rogers W., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
2. Thannickal TC., Moore RY., Nienhuis R., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
3. Cao M. Advances in narcolepsy. Med Clin North Am 2010, 94:541-555.
4. Mignot E., Wang C., Rattazzi C., et al. Genetic linkage of autosomal recessive canine narcolepsy with a mu immunoglobulin heavy-chain switch-like segment. Proc Natl Acad Sci U S A 1991, 88:3475-3478.
5. Mignot E., Kimura A., Lattermann A., et al. Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 1997, 49:329-341.
6. Matsuki K., Grumet FC., Lin X., et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992, 339:1052.
7. Mignot E., Lin L., Rogers W., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686-699.
8. Hallmayer J., Faraco J., Lin L., et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708-711.
9. Aran A., Lin L., Nevsimalova S., et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32:979-983.
10. Dauvilliers Y., Montplaisir J., Cochen V., et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33:1428-1430.
11. Deloumeau A., Bayard S., Coquerel Q., et al. Increased immune complexes of hypocretin autoantibodies in narcolepsy. PLoS One 2010, 5. e13320.
12. Kawashima M., Lin L., Tanaka S., et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep 2010, 33:869-874.
13. Lim AS., Scammell TE. The trouble with Tribbles: Do antibodies against TRIB2 cause narcolepsy?. Sleep 2010, 33:857-858.
14. Toyoda H., Tanaka S., Miyagawa T., Honda Y., Tokunaga K., Honda M. Anti-Tribbles homolog 2 autoantibodies in Japanese patients with narcolepsy. Sleep 2010, 33:875-878.
15. Guilleminault C., Pelayo R. Narcolepsy in children: A practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000, 2:1-9.
16. Vetrugno R., D'Angelo R., Moghadam KK., et al. Behavioural and neurophysiological correlates of human cataplexy: A video-polygraphic study. Clin Neurophysiol 2010, 121:153-162.
17. Aran A., Einen M., Lin L., Plazzi G., Nishino S., Mignot E. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: A retrospective study of 51 children. Sleep 2010, 33:1457-1464.
18. Longstreth WT., Ton TG., Koepsell TD. Narcolepsy and streptococcal infections. Sleep 2009, 32:1548.
19. Guilleminault C., Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998, 43:135-142.
20. Plazzi G., Tonon C., Rubboli G., et al. Narcolepsy with cataplexy associated with holoprosencephaly misdiagnosed as epileptic drop attacks. Mov Disord 2010, 25:780-782.
21. Hirst J., Mignot E., Stein MT. Episodic hypersomnia and unusual behaviors in a 14-year-old adolescent. J Dev Behav Pediatr 2010, 31:S18-S20.
22. Vendrame M., Havaligi N., Matadeen-Ali C., Adams R., Kothare SV. Narcolepsy in children: A single-center clinical experience. Pediatr Neurol 2008, 38:314-320.
23. Silber MH., Krahn LE., Olson EJ., Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study. Sleep 2002, 25:197-202.
24. Okun ML., Lin L., Pelin Z., Hong S., Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
25. Yoss RE., Daly DD. Narcolepsy in children. Pediatrics 1960, 25:1025-1033.
26. Morrish E., King MA., Smith IE., Shneerson JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004, 5:37-41.
27. Serra L., Montagna P., Mignot E., Lugaresi E., Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord 2008, 23:858-865.
28. International Classification of Sleep Disorders 2005, American Academy of Sleep Medicine, Westchester, IL. 2nd ed.
29. Aldrich MS. The neurobiology of narcolepsy-cataplexy. Prog Neurobiol 1993, 41:533-541.
30. Singh M., Drake CL., Roth T. The prevalence of multiple sleep-onset REM periods in a population-based sample. Sleep 2006, 29:890-895.
31. Bishop C., Rosenthal L., Helmus T., Roehrs T., Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996, 19:727-730.
32. Moscovitch A., Partinen M., Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993, 43:55-60.
33. Dauvilliers Y., Gosselin A., Paquet J., Touchon J., Billiard M., Montplaisir J. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004, 62:46-50.
34. Nishino S., Ripley B., Overeem S., Lammers GJ., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
35. Mignot E., Lammers GJ., Ripley B., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
36. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
37. Challamel MJ., Mazzola ME., Nevsimalova S., Cannard C., Louis J., Revol M. Narcolepsy in children. Sleep 1994, 17:S17-S20.
38. Nishino S., Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005, 9:269-310.
39. Kanbayashi T., Shimohata T., Nakashima I., et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: New neurochemical and immunological implications. Arch Neurol 2009, 66:1563-1566.
40. Lecendreux M., Maret S., Bassetti C., Mouren MC., Tafti M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003, 12:347-348.
41. Dauvilliers Y., Carlander B., Rivier F., Touchon J., Tafti M. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004, 56:905-908.
42. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 2006, 60:153.
43. Fronczek R., Verschuuren J., Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007, 254:1607-1608.
44. Plazzi G., Poli F., Franceschini C., et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008, 255:1549-1554.
45. Dauvilliers Y., Abril B., Mas E., Michel F., Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009, 73:1333-1334.
46. Littner M., Johnson SF., McCall WV., et al. Practice parameters for the treatment of narcolepsy: An update for 2000. Sleep 2001, 24:451-466.
47. Peterson PC., Husain AM. Pediatric narcolepsy. Brain Dev 2008, 30:609-623.
48. Greenhill LL., Pliszka S., Dulcan MK., et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002, 41:26S-49S.
49. Wise MS., Arand DL., Auger RR., Brooks SN., Watson NF. Treatment of narcolepsy and other hypersomnias of central origin. Sleep 2007, 30:1712-1727.
50. Spiller HA., Borys D., Griffith JR., et al. Toxicity from modafinil ingestion. Clin Toxicol (Phila) 2009, 47:153-156.
51. Rugino T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr Dis Treat 2007, 3:293-301.
52. Black J., Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006, 29:939-946.
53. U.S. Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000, 54:1166-1175. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy.
54. Broughton RJ., Fleming JA., George CF., et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997, 49:444-451.
55. Kahbazi M., Ghoreishi A., Rahiminejad F., Mohammadi MR., Kamalipour A., Akhondzadeh S. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009, 168:234-237.
56. Biederman J., Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008, 152:394-399.
57. Amiri S., Mohammadi MR., Mohammadi M., Nouroozinejad GH., Kahbazi M., Akhondzadeh S. Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: A double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:145-149.
58. Wigal SB., Biederman J., Swanson JM., Yang R., Greenhill LL. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: Pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry 2006, 8:352-360.
59. Lankford DA. Armodafinil: A new treatment for excessive sleepiness. Expert Opin Investig Drugs 2008, 17:565-573.
60. Ivanenko A., Tauman R., Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med 2003, 4:579-582.
61. Pelayo R., Dubik M. Pediatric sleep pharmacology. Semin Pediatr Neurol 2008, 15:79-90.
62. Lammers GJ., Bassetti C., Billiard M., et al. Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Med 2010, 11:105-106. author reply 6-8.
63. Lammers GJ., Arends J., Declerck AC., Ferrari MD., Schouwink G., Troost J. Gamma-hydroxybutyrate and narcolepsy: A double-blind placebo-controlled study. Sleep 1993, 16:216-220.
64. The U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004, 5:119-123.
65. The U.S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002, 25:42-49.
66. Huang YS., Guilleminault C. Narcolepsy: Action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol 2009, 41:9-16.
67. Scharf MB., Lai AA., Branigan B., Stover R., Berkowitz DB. Pharmacokinetics of gamma-hydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998, 21:507-514.
68. Billiard M. Narcolepsy: Current treatment options and future approaches. Neuropsychiatr Dis Treat 2008, 4:557-566.
69. Fujiki N., Yoshida Y., Ripley B., Mignot E., Nishino S. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003, 26:953-959.
70. Schatzberg SJ., Cutter-Schatzberg K., Nydam D., et al. The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004, 18:586-588.
71. Mieda M., Willie JT., Hara J., Sinton CM., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654.
72. Liu M., Thankachan S., Kaur S., et al. Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008, 28:1382-1393.
73. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007, 8:373-399.
74. Dhuria SV., Hanson LR., Frey WH. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009, 98:2501-2515.
75. Deadwyler SA., Porrino L., Siegel JM., Hampson RE. Systemic and nasal delivery of orexin-A (hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007, 27:14239-14247.